Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18657123 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | May 2024 | February 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 18622139 | Formulation of Resiniferatoxin | March 2024 | May 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18600974 | HETEROCYCLIC PDK1 INHIBITORS FOR USE TO TREAT CANCER | March 2024 | June 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18430855 | OPHTHALMIC SOLUTION OF DIFLUPREDNATE | February 2024 | April 2025 | Allow | 14 | 2 | 0 | Yes | No |
| 18531259 | COMPOSITIONS COMPRISING 15-OHEPA AND METHODS OF USING THE SAME | December 2023 | June 2025 | Abandon | 19 | 2 | 0 | Yes | No |
| 18530663 | USE OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR TREATMENT OF VASCULAR MALFORMATIONS | December 2023 | April 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18386101 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | November 2023 | February 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18378480 | EFFICIENT ANTI-BACTERIAL HYDROXY ACID ESTER OLIGOMER | October 2023 | March 2025 | Allow | 17 | 1 | 0 | Yes | No |
| 18456612 | COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES THEREOF | August 2023 | February 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18450379 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS | August 2023 | March 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18233398 | CALCIUM SUCCINATE MONOHYDRATE FORMULATION | August 2023 | October 2024 | Abandon | 14 | 2 | 0 | No | No |
| 18447059 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO AGING | August 2023 | December 2024 | Abandon | 17 | 1 | 1 | No | No |
| 18363328 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | August 2023 | February 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18345623 | TOPICAL COMPOSITIONS COMPRISING BIMATOPROST AND METHODS FOR STIMULATING HAIR GROWTH THEREWITH | June 2023 | March 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18340308 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | June 2023 | January 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18210217 | CO-CRYSTALS | June 2023 | December 2024 | Allow | 18 | 0 | 1 | Yes | No |
| 18210046 | COMBINATION THERAPY FOR THE TREATMENT OF TINNITUS AND OTHER MEDICAL CONDITIONS | June 2023 | October 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18302691 | (2S)-1-[4-(3,4-DICHLOROPHENYL)PIPERIDIN-1-YL]-3-[2-(5-METHYL-1,3,4-OXADIAZOL-2-YL)BENZO[B]FURAN-4-YLOXY] PROPAN-2-OL OR ITS METABOLITE FOR TREATING ANXIETY DISORDERS | April 2023 | June 2025 | Abandon | 26 | 2 | 0 | No | No |
| 18163811 | STABLE PHARMACEUTICAL COMPOSITIONS OF HYDROXYUREA | February 2023 | March 2025 | Abandon | 25 | 3 | 1 | Yes | No |
| 18158889 | ANTIMICROBIAL COMPOSITIONS CONTAINING CATIONIC ACTIVE INGREDIENTS | January 2023 | August 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 18095498 | PHOSPHOLIPID COMPOSITIONS FOR TREATING INFECTIONS AND INFLAMMATION | January 2023 | December 2024 | Abandon | 23 | 1 | 1 | No | No |
| 18077832 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDEHYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD), NASH, ALD OR CONDITIONS RELATED TO THE LIVER | December 2022 | April 2025 | Allow | 28 | 1 | 1 | No | No |
| 17897116 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | August 2022 | November 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17883245 | PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) INHIBITOR AND METHOD OF USE | August 2022 | April 2025 | Allow | 32 | 2 | 1 | Yes | No |
| 17789631 | DOSAGE REGIME WITH ESKETAMINE FOR TREATING MAJOR DEPRESSIVE DISORDER | June 2022 | December 2024 | Allow | 29 | 2 | 0 | Yes | No |
| 17839202 | FUSED CYCLOOCTYNE COMPOUNDS AND THEIR USE IN METAL-FREE CLICK REACTIONS | June 2022 | September 2024 | Allow | 27 | 2 | 0 | Yes | No |
| 17669425 | USE OF LOW DOSE EMETINE FOR INHIBITION OF HUMAN CYTOMEGALOVIRUS (HCMV) | February 2022 | September 2024 | Allow | 31 | 1 | 1 | Yes | No |
| 17555898 | INHIBITION OF BETA-2 NICOTINIC ACETYLCHOLINE RECEPTORS TO TREAT ALZHEIMER'S DISEASE PATHOLOGY | December 2021 | April 2025 | Abandon | 40 | 3 | 0 | No | No |
| 17606125 | NOVEL PHARMACEUTICAL COMPOSITION | October 2021 | May 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17510375 | Efficient anti-bacterial hydroxy acid ester oligomer | October 2021 | November 2024 | Abandon | 37 | 2 | 0 | No | No |
| 17604618 | LIQUID SILDENAFIL CITRATE COMPOSITIONS | October 2021 | May 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17369268 | ANAPLEROTIC AGENTS FOR TREATMENT OF DISORDERS OF PROPIONATE AND LONG CHAIN FAT METABOLISM | July 2021 | March 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17289606 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF PAIN | April 2021 | April 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17230840 | INHIBITION OF AUTOPHAGY USING PHOSPHOLIPASE A2 INHIBITORS | April 2021 | February 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17223096 | STABLE READY TO USE CYCLOPHOSPHAMIDE LIQUID FORMULATIONS | April 2021 | April 2025 | Allow | 48 | 3 | 0 | No | No |
| 17279732 | DERIVATIVE OF SARSASAPOGENIN, PHARMACEUTICAL COMPOSITION AND USE THEREOF | March 2021 | June 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17274725 | COMBINED SIROLIMUS AND NINTEDANIB THERAPY FOR VASCULAR LESIONS AND HEREDITARY HEMORRHAGIC TELANGIECTASIA | March 2021 | November 2024 | Allow | 44 | 1 | 1 | Yes | No |
| 17191084 | Methods and Compositions for Treatment of Asthma or Parkinson's Disease | March 2021 | January 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17097080 | COMPOUNDS FOR THE TREATMENT OF CANCER | November 2020 | April 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 16949603 | METHOD OF TREATING TEMPOROMANDIBULAR JOINT DISORDERS | November 2020 | October 2024 | Abandon | 47 | 0 | 1 | No | No |
| 17031642 | USE OF 2-HYDROXYBENZYLAMINE FOR THE TREATMENT OF SYSTEMIC LUPUS | September 2020 | November 2024 | Abandon | 49 | 4 | 0 | Yes | No |
| 16963672 | SYNERGISTIC PHARMACEUTICAL COMBINATION OF THE ACTIVE ENANTIOMER S-KETOROLAC TROMETHAMINE AND TRAMADOL CHLORHYDRATE | July 2020 | December 2024 | Abandon | 53 | 6 | 0 | Yes | No |
| 16757312 | COMPOSITIONS AND METHODS FOR BROAD-SPECTRUM ANTIVIRAL THERAPY | April 2020 | September 2024 | Allow | 53 | 3 | 1 | Yes | Yes |
| 16852225 | METHODS OF TREATING OCULAR CONDITIONS | April 2020 | January 2025 | Abandon | 57 | 3 | 1 | No | No |
| 16641145 | ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN DISEASE TREATMENTS | February 2020 | April 2025 | Allow | 60 | 4 | 1 | Yes | Yes |
| 16630114 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | January 2020 | January 2025 | Allow | 60 | 6 | 0 | Yes | No |
| 16490655 | Methods of Treating Conditions Associated with Leaky Gut Barrier | September 2019 | December 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16347755 | USE OF 2-HYDROXYBENZYLAMINE IN THE TREATMENT AND PREVENTION OF PULMONARY HYPERTENSION | May 2019 | May 2025 | Abandon | 60 | 5 | 1 | Yes | Yes |
| 16225772 | THERAPEUTIC AGENT FOR BILE DUCT CANCER | December 2018 | October 2019 | Allow | 10 | 1 | 0 | No | No |
| 16300935 | TREATMENT OF MINIERE'S DISEASE | November 2018 | June 2025 | Allow | 60 | 4 | 1 | Yes | Yes |
| 16067994 | INHIBITORS OF ATAXIA-TELANGIECTASIA MUTATED AND RAD3-RELATED PROTEIN KINASE (ATR) FOR USE IN METHODS OF TREATING CANCER | July 2018 | October 2024 | Allow | 60 | 6 | 1 | Yes | No |
| 15978854 | PHARMACEUTICAL COMPOSITION COMPRISING AMORPHOUS LENALIDOMIDE AND AN ANTIOXIDANT | May 2018 | March 2019 | Allow | 11 | 1 | 1 | Yes | No |
| 15568025 | NOVEL COMPOUNDS | October 2017 | May 2019 | Allow | 19 | 1 | 1 | Yes | No |
| 15547139 | THERAPEUTIC AGENT FOR BILE DUCT CANCER | July 2017 | September 2018 | Allow | 14 | 1 | 1 | Yes | No |
| 15642899 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | July 2017 | January 2019 | Allow | 18 | 2 | 1 | Yes | No |
| 15514259 | AQUEOUS COMPOSITION CONTAINING RIPASUDIL, OR A SALT, OR A SOLVATE THEREOF | March 2017 | March 2019 | Allow | 24 | 3 | 0 | No | No |
| 15217301 | FORMULATIONS FOR SOLUBILIZING HORMONES | July 2016 | February 2019 | Allow | 30 | 3 | 1 | Yes | No |
| 14913135 | AMIDE DERIVATIVES AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | February 2016 | May 2018 | Allow | 27 | 1 | 2 | Yes | No |
| 14895695 | MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFIA, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | December 2015 | August 2017 | Allow | 20 | 1 | 1 | Yes | No |
| 14946586 | LAQUINIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) PATIENTS WITH A HIGH DISABILITY STATUS | November 2015 | November 2016 | Allow | 12 | 2 | 0 | Yes | No |
| 14840118 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | August 2015 | March 2017 | Allow | 19 | 1 | 1 | Yes | No |
| 14423674 | Methods and Compositions for Treating Pain | February 2015 | September 2016 | Allow | 19 | 1 | 1 | Yes | No |
| 14626522 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL AND METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER | February 2015 | October 2018 | Allow | 44 | 4 | 1 | Yes | No |
| 14463959 | ALPROSTADIL FOR TREATMENT OF PREMATURE EJACULATION | August 2014 | January 2015 | Allow | 5 | 1 | 0 | Yes | No |
| 14463966 | ALPROSTADIL AND LIDOCAINE TREATMENT OF PREMATURE EJACULATION | August 2014 | February 2015 | Allow | 6 | 1 | 0 | Yes | No |
| 14463921 | ALPROSTADIL AND DYCLONINE FOR TREATMENT OF PREMATURE EJACULATION | August 2014 | January 2015 | Allow | 5 | 1 | 0 | Yes | No |
| 14377143 | FORMYLATED XANTHOCILLIN ANALOGUES AS NEUROPROTECTIVE AGENTS | August 2014 | May 2016 | Allow | 21 | 1 | 1 | Yes | No |
| 14363427 | ANTIMICROBIAL COMPOSITION | June 2014 | September 2016 | Allow | 28 | 2 | 1 | Yes | No |
| 14283943 | COELENTERAZINE ANALOGS AND MANUFACTURING METHOD THEREOF | May 2014 | May 2015 | Allow | 12 | 0 | 0 | Yes | No |
| 14271570 | SULFAMIDES AS TRPM8 MODULATORS | May 2014 | September 2015 | Allow | 16 | 1 | 0 | No | No |
| 14271486 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS | May 2014 | May 2015 | Allow | 12 | 0 | 0 | Yes | No |
| 14179088 | METHOD OF IMPROVING COGNITION AND INCREASING DENDRITIC COMPLEXITY IN HUMANS WITH DOWN SYNDROME AND COMPOSITIONS THEREFOR | February 2014 | December 2015 | Allow | 22 | 1 | 1 | Yes | No |
| 14151438 | TOPICAL SKIN CARE COMPOSITION | January 2014 | February 2016 | Allow | 25 | 1 | 1 | No | No |
| 14097397 | Inhibitors of PDE4 Enzyme and Antagonists of Muscarinic M3 Receptor | December 2013 | June 2015 | Allow | 18 | 0 | 1 | Yes | No |
| 14118379 | HYPOPHOSPHOROUS ACID DERIVATIVES HAVING ANTIHYPERALGIC ACTIVITY AND BIOLOGICAL APPLICATIONS THEREOF | November 2013 | August 2015 | Allow | 21 | 1 | 0 | Yes | No |
| 13971870 | METHYLNALTREXONE NASAL FORMULATIONS, METHODS OF MAKING, AND USE THEREOF | August 2013 | August 2019 | Allow | 60 | 4 | 1 | No | Yes |
| 13821682 | INHIBITORS OF VIRAL ENTRY INTO MAMMALIAN CELLS | August 2013 | September 2015 | Allow | 31 | 1 | 1 | Yes | No |
| 13963226 | METHOD OF USING AN INDOLINONE MOLECULE AND DERIVATIVES FOR INHIBITING LIVER FIBROSIS AND HEPATITIS | August 2013 | March 2016 | Allow | 31 | 1 | 1 | Yes | No |
| 13939962 | ARYL SULTAM DERIVATIVES AS RORC MODULATORS | July 2013 | December 2014 | Allow | 17 | 0 | 0 | Yes | No |
| 13923196 | NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | June 2013 | January 2014 | Allow | 7 | 0 | 0 | Yes | No |
| 13902270 | TRANSITION METAL COMPLEXES OF A BIS[THIOHYDRAZIDE AMIDE] COMPOUND | May 2013 | April 2014 | Allow | 10 | 1 | 0 | No | No |
| 13819120 | TRIAZOLOPYRAZINE DERIVATIVES | May 2013 | October 2014 | Allow | 20 | 1 | 1 | Yes | No |
| 13882567 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | April 2013 | May 2015 | Allow | 25 | 2 | 1 | Yes | No |
| 13867293 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | April 2013 | February 2014 | Allow | 10 | 1 | 1 | Yes | No |
| 13855559 | PROGESTERONE ANTAGONISTS SUCH AS CDB-4124 IN THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, DYSMENORRHEA, BREAST CANCER, ETC. | April 2013 | December 2013 | Allow | 9 | 0 | 0 | Yes | No |
| 13851988 | SULFAMIDES AS TRPM8 MODULATORS | March 2013 | January 2014 | Allow | 10 | 0 | 1 | Yes | No |
| 13787877 | PEPTIDOMIMETIC COMPOUNDS AS IMMUNOMODULATORS | March 2013 | January 2015 | Allow | 23 | 1 | 1 | Yes | No |
| 13785422 | PHENICOL ANTIBACTERIALS | March 2013 | February 2015 | Allow | 24 | 1 | 1 | Yes | No |
| 13820873 | THERAPEUTIC AGENT FOR PAIN | March 2013 | May 2017 | Allow | 50 | 5 | 1 | Yes | No |
| 13643546 | FUSED CYCLOOCTYNE COMPOUNDS AND THEIR USE IN METAL-FREE CLICK REACTIONS | February 2013 | July 2014 | Allow | 20 | 0 | 1 | Yes | No |
| 13761306 | PEST CONTROL AGENT | February 2013 | March 2015 | Allow | 25 | 1 | 1 | Yes | No |
| 13760781 | NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | February 2013 | April 2013 | Allow | 3 | 0 | 0 | Yes | No |
| 13731545 | MACROCYCLIC COMPOUNDS AND METAL COMPLEXES FOR BIOIMAGING AND BIOMEDICAL APPLICATIONS | December 2012 | February 2015 | Allow | 25 | 2 | 1 | Yes | No |
| 13632546 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | October 2012 | January 2013 | Allow | 4 | 0 | 1 | Yes | No |
| 13636305 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATEMENT OF WOUNDS | September 2012 | April 2015 | Allow | 30 | 2 | 1 | Yes | Yes |
| 13635894 | NEW DERIVATIVES OF PROPARGYLAMINE HAVING NEUROPROTECTIVE CAPACITY FOR THE TREATMENT OF ALZHEIMER'S AND PARKINSON'S DISEASES | September 2012 | December 2014 | Allow | 27 | 1 | 1 | Yes | No |
| 13607859 | N-(5-CYCLOALKYL)-PYRIDIN-3-YL CARBOXAMIDES | September 2012 | March 2013 | Allow | 6 | 0 | 0 | Yes | No |
| 13606947 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | September 2012 | September 2014 | Allow | 24 | 1 | 1 | Yes | No |
| 13582477 | SYNERGISTIC EFFECT OF TOCOTRIENOLS AND CURCUMIN | September 2012 | August 2014 | Allow | 23 | 2 | 0 | Yes | No |
| 13520136 | SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS | August 2012 | December 2014 | Allow | 30 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NEAGU, IRINA.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 21.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner NEAGU, IRINA works in Art Unit 1629 and has examined 122 patent applications in our dataset. With an allowance rate of 80.3%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 25 months.
Examiner NEAGU, IRINA's allowance rate of 80.3% places them in the 43% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by NEAGU, IRINA receive 1.71 office actions before reaching final disposition. This places the examiner in the 49% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by NEAGU, IRINA is 25 months. This places the examiner in the 64% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +55.8% benefit to allowance rate for applications examined by NEAGU, IRINA. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 29.7% of applications are subsequently allowed. This success rate is in the 48% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 42.4% of cases where such amendments are filed. This entry rate is in the 58% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 90.9% of appeals filed. This is in the 81% percentile among all examiners. Of these withdrawals, 80.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 33.3% are granted (fully or in part). This grant rate is in the 26% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.